Humna Shafaq
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Humna Shafaq has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Andrés Pérez-López
Division of Microbiology, Department of Pathology, Sidra Medicine, Doha, Qatar
1 shared publication - Anju Sharma
Division of Microbiology, Sidra Medicine, Doha P.O. Box 26999, Qatar
1 shared publication - Clement K. M. Tsui
Infectious Diseases Research Laboratory, National Centre for Infectious Diseases, Singapore 308442, Singapore
1 shared publication - Diyna Altrmanini
Division of Microbiology, Sidra Medicine, Doha P.O. Box 26999, Qatar
1 shared publication - Elaine Mariano
Division of Microbiology, Sidra Medicine, Doha P.O. Box 26999, Qatar
1 shared publication - Hiam Chemaitelly
Infectious Disease Epidemiology Group, Weill Cornell Medicine - Qatar, Cornell University, Doha, Qatar
1 shared publication
Latest Publications
- Open Access
- 9 November 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (11) , 1114
Aztreonam–Avibactam Susceptibility and Genomics of NDM-Producing Escherichia coli in Pediatric Patients from Gaza and Qatar
Background: Aztreonam–avibactam (ATM/AVI) emerges as a promising treatment for pediatric infections caused by New Delhi metallo-beta-lactamase (NDM)-producing Escherichia coli once approved for children aged ≤18 years. Methods: We assessed in vitro susceptibility to ATM/AVI and characterized the molecular resistance mechanisms in NDM-producing E. coli recovered from admission rectal screening swabs of war-affected Palestinian children (December 2023–July 2024) and children in Sidra Medicine’s catchment population in Doha (January 2022–December 2025). Minimum inhibitory concentrations (MICs) were determined using the MIC Test Strip method and interpreted according to the European Committee on Antimicrobial Susceptibility Testing breakpoints. Penicillin-binding protein 3 (PBP3) insertions and the co-production of CMY-type plasmid-mediated AmpC beta-lactamases (pAmpC) were characterized by short-read whole-genome sequencing. Linear regression estimated mean differences in log2-transformed MICs by PBP3 insertion and CMY status. Results: A total of 74 non-duplicate NDM-producing E. coli isolates were analyzed, of which 69 (93.2%) produced NDM-5. Overall, 18 (24.3%) isolates exhibited resistance to ATM/AVI (MIC > 4 mg/L). Sixty-six (89.2%) isolates harbored PBP3 insertions, comprising YRIN (48 isolates; 64.9%), mainly detected in ST167, and YRIK (18 isolates; 24.3%), mainly detected in ST405. CMY-42 (17 isolates) and CMY-145 (eight isolates) were exclusively identified in isolates concurrently harboring PBP3 insertions. ATM/AVI log2 MICs were significantly higher in isolates harboring PBP3 insertions, particularly YRIK, and increased further when combined with CMY-42 or CMY-145. Conclusions: Our study reveals a high proportion of NDM-producing E. coli belonging to high-risk clones harboring PBP3 mutations, either alone or in combination with CMY-type pAmpC, driving substantial increases in ATM/AVI MICs across two distinct Middle Eastern pediatric cohorts. Large-scale regional genomic surveillance is needed to determine the extent of convergent resistance mechanisms associated with reduced susceptibility to ATM/AVI and other newer β-lactams targeting PBP3.
- 9 November 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (11) , 1114
Open AccessAztreonam–Avibactam Susceptibility and Genomics of NDM-Producing Escherichia coli in Pediatric Patients from Gaza and Qatar
Background: Aztreonam–avibactam (ATM/AVI) emerges as a promising treatment for pediatric infections caused by New Delhi metallo-beta-lactamase (NDM)-producing Escherichia coli once approved for children aged ≤18 years. Methods: We assessed in vitro susceptibility to ATM/AVI and characterized the molecular resistance mechanisms in NDM-producing E. coli recovered from admission rectal screening swabs of war-affected Palestinian children (December 2023–July 2024) and children in Sidra Medicine’s catchment population in Doha (January 2022–December 2025). Minimum inhibitory concentrations (MICs) were determined using the MIC Test Strip method and interpreted according to the European Committee on Antimicrobial Susceptibility Testing breakpoints. Penicillin-binding protein 3 (PBP3) insertions and the co-production of CMY-type plasmid-mediated AmpC beta-lactamases (pAmpC) were characterized by short-read whole-genome sequencing. Linear regression estimated mean differences in log2-transformed MICs by PBP3 insertion and CMY status. Results: A total of 74 non-duplicate NDM-producing E. coli isolates were analyzed, of which 69 (93.2%) produced NDM-5. Overall, 18 (24.3%) isolates exhibited resistance to ATM/AVI (MIC > 4 mg/L). Sixty-six (89.2%) isolates harbored PBP3 insertions, comprising YRIN (48 isolates; 64.9%), mainly detected in ST167, and YRIK (18 isolates; 24.3%), mainly detected in ST405. CMY-42 (17 isolates) and CMY-145 (eight isolates) were exclusively identified in isolates concurrently harboring PBP3 insertions. ATM/AVI log2 MICs were significantly higher in isolates harboring PBP3 insertions, particularly YRIK, and increased further when combined with CMY-42 or CMY-145. Conclusions: Our study reveals a high proportion of NDM-producing E. coli belonging to high-risk clones harboring PBP3 mutations, either alone or in combination with CMY-type pAmpC, driving substantial increases in ATM/AVI MICs across two distinct Middle Eastern pediatric cohorts. Large-scale regional genomic surveillance is needed to determine the extent of convergent resistance mechanisms associated with reduced susceptibility to ATM/AVI and other newer β-lactams targeting PBP3.